This clinical trial is focused on studying a type of cancer called neuroblastoma, which is a cancer that most commonly affects children. The study is testing a treatment that combines a medication called dinutuximab beta with other chemotherapy drugs. Chemotherapy is a type of cancer treatment that uses drugs to destroy cancer cells. The chemotherapy drugs being used in this study include dacarbazine, etoposide, cisplatin, vincristine sulfate, ifosfamide, carboplatin, doxorubicin hydrochloride, and cyclophosphamide. These drugs are given to patients to see how well they work together with dinutuximab beta in treating newly diagnosed high-risk neuroblastoma.

The purpose of the study is to find out how safe and tolerable the combination of dinutuximab beta and chemotherapy is for patients, and to determine the best dose to use. Patients in the study will receive the treatment in cycles, which means they will have periods of receiving the medication followed by periods of rest. The study will monitor patients for any side effects and how their cancer responds to the treatment. Some patients may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatment.

The study will take place over several years, with patients being closely monitored throughout the process. The goal is to gather information on the safety and effectiveness of the treatment combination, which could lead to better treatment options for children with high-risk neuroblastoma in the future. Participants will be required to attend regular follow-up appointments to track their progress and any changes in their condition.